Lallemand Health Solutions at Pharmabiotics: Join in To Learn More About Discovery, Development & Preclinical Research

Annie Tremblay, Scientific Writer at Lallemand Health Solutions will present Preclinical and Clinical Studies Shed Light on Potential Modes of Action of L. rhamnosus HA-114 in Metabolic Regulation and Neuroprotection” at the Pharmabiotics Conference and Partnering 2022, in Lyon, France, on April 20 at 3:00 p.m. CET.

 “I am honored to present to members from academia and industry, and to other microbiome aficionados who will be gathering for the Pharmabiotics event in Lyon this year. I will summarize the results of a recent clinical study as well as preclinical data on our probiotic strain L. rhamnosus HA-114 that was shown to support weight management efforts. These results are very interesting because they could place HA-114 at the intersection between metabolic health and the gut-brain axis.” said Mrs. Tremblay.

Indeed, Lallemand Health Solutions’ rising star L. rhamnosus HA-114 was demonstrated to improve eating and mood-related behaviors in adults with overweight during weight loss, therefore supporting weight management efforts by restoring the balance of eating behaviors through the brain-gut axis. More info here.

The Pharmabiotics Conference program promises to explore the high potential of the microbiome and its role in human health, representing a paradigm shift in how medicines will be developed. Pharmabiotics Conference & Partnering is bringing together players from academia and industry to make microbiome-based drug products a therapeutic reality. The scientific program is organized in such a way to reflect the R&D continuum, addressing each major phase of scientific advances, challenges, and innovations across all stages of microbiome product development.

More information and registration here.


About Annie Tremblay, PhD, MWC

Annie Tremblay joined Lallemand Health Solutions in October 2018. She holds a Ph.D. in Biochemistry from McGill University, a M.Sc. in Pharmaceutical Sciences, and a B.Sc. in Biomedical Sciences from the University of Montreal. She held a post-doctoral fellowship at the Boston Children’s Hospital, in affiliation with the Harvard Department of Stem Cell and Regenerative Biology. She also worked as a scientific writer in clinical research at the CHUM for over two years before joining the Rosell® Institute for Microbiome and Probiotics by Lallemand. As a certified professional medical writer (AMWA), Annie is responsible for writing various scientific and medical content for both the clinical and the pre-clinical research platforms of the Lallemand Health Solutions’ R&D department.

About The Rosell® Institute for Microbiome and Probiotics by Lallemand
One of Lallemand Health Solutions’ two research and development centers is located at the National Research Council of Canada in Montreal and develops, in partnership with key scientific experts, research programs to study the human microbiome and better understand the properties, the mechanisms and effects of probiotics to improve or maintain the health of populations, or specific therapeutic areas. The various Lallemand Health Solutions probiotics have already been studied in multiple research programs including 160 clinical studies leading to around 350 scientific publications.

About Lallemand Health Solutions
Lallemand Health Solutions is a vertically integrated probiotic manufacturer specialized in the research, development, production and marketing of probiotic yeast and bacteria. Its ready-to-market and custom probiotic formulations target specific populations and health segments including gut health, immune health, mental health, women’s health, skin health, oral health, metabolic health and sport. Probiotics are manufactured in cutting-edge plants certified to the highest quality. More than 600 probiotic formulas are currently marketed in over 60 countries across five continents.



Marilou Luneau, Content Manager, Lallemand Health Solutions